MX2020011205A - Inhibidor de la interaccion proteina-proteina fenil triazol mll1-wdr5. - Google Patents
Inhibidor de la interaccion proteina-proteina fenil triazol mll1-wdr5.Info
- Publication number
- MX2020011205A MX2020011205A MX2020011205A MX2020011205A MX2020011205A MX 2020011205 A MX2020011205 A MX 2020011205A MX 2020011205 A MX2020011205 A MX 2020011205A MX 2020011205 A MX2020011205 A MX 2020011205A MX 2020011205 A MX2020011205 A MX 2020011205A
- Authority
- MX
- Mexico
- Prior art keywords
- protein
- mll1
- wdr5
- interaction inhibitor
- phenyl triazole
- Prior art date
Links
- 230000004850 protein–protein interaction Effects 0.000 title abstract 3
- LUEYUHCBBXWTQT-UHFFFAOYSA-N 4-phenyl-2h-triazole Chemical compound C1=NNN=C1C1=CC=CC=C1 LUEYUHCBBXWTQT-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000003285 pharmacodynamic effect Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
La invención se refiere al campo de la química médica, en particular a un inhibidor de la interacción proteína-proteína (I) de fenil triazol MLL1-WDR5 y un método de preparación del mismo, y los experimentos de farmacodinamia demuestran que el compuesto de la invención tiene una proteína MLL1-WDR5 relativamente fuerte. -actividad de inhibición de la interacción de proteínas. (ver Fórmula).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810365880.0A CN108715585A (zh) | 2018-04-23 | 2018-04-23 | 苯基联三氮唑类mll1-wdr5蛋白-蛋白相互作用抑制剂 |
| PCT/CN2018/123500 WO2019205687A1 (zh) | 2018-04-23 | 2018-12-25 | 苯基联三氮唑类mll1-wdr5蛋白-蛋白相互作用抑制剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020011205A true MX2020011205A (es) | 2021-02-09 |
Family
ID=63899366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020011205A MX2020011205A (es) | 2018-04-23 | 2018-12-25 | Inhibidor de la interaccion proteina-proteina fenil triazol mll1-wdr5. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11479545B2 (es) |
| EP (1) | EP3786157B1 (es) |
| JP (1) | JP7274765B2 (es) |
| KR (1) | KR20210019414A (es) |
| CN (2) | CN108715585A (es) |
| AU (1) | AU2018420231B2 (es) |
| BR (1) | BR112020021569A2 (es) |
| CA (1) | CA3097925A1 (es) |
| CL (1) | CL2020002736A1 (es) |
| CO (1) | CO2020014430A2 (es) |
| EA (1) | EA202092317A1 (es) |
| IL (1) | IL278255B2 (es) |
| MX (1) | MX2020011205A (es) |
| PH (1) | PH12020551756A1 (es) |
| SG (1) | SG11202010492SA (es) |
| WO (1) | WO2019205687A1 (es) |
| ZA (1) | ZA202006581B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019261273B2 (en) | 2018-04-23 | 2023-03-09 | Celgene Corporation | Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma |
| CN108715585A (zh) | 2018-04-23 | 2018-10-30 | 中国药科大学 | 苯基联三氮唑类mll1-wdr5蛋白-蛋白相互作用抑制剂 |
| CN109734674B (zh) * | 2019-02-26 | 2022-08-26 | 中国药科大学 | 苯胺类wdr5蛋白-蛋白相互作用抑制剂及其制法和用途 |
| US20230286948A1 (en) * | 2022-03-14 | 2023-09-14 | Huyabio International, Llc | Haloalkylpyridyl triazole mll1-wdr5 protein-protein interaction inhibitor |
| WO2023177593A1 (en) * | 2022-03-14 | 2023-09-21 | Huyabio International, Llc | Phenyl triazole mll1-wdr5 protein-protein interaction inhibitor |
| WO2024002379A1 (zh) * | 2022-07-01 | 2024-01-04 | 甘李药业股份有限公司 | 一种用作wdr5抑制剂的化合物或其可药用盐及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1692116B1 (en) * | 2003-12-03 | 2011-03-09 | Boehringer Ingelheim Pharmaceuticals Inc. | 1,2,3-triazole amide derivatives as inhibitors of cytokine production |
| WO2011149827A1 (en) | 2010-05-24 | 2011-12-01 | Glaxosmithkline Llc | Compounds and methods |
| CN104844573A (zh) | 2015-04-17 | 2015-08-19 | 中国药科大学 | 嘧啶类btk抑制剂、其制备方法及医药用途 |
| CN105175284B (zh) * | 2015-07-21 | 2017-06-16 | 中国药科大学 | 酰胺类化合物、制备方法及其医药用途 |
| RU2018128334A (ru) | 2016-02-09 | 2020-03-10 | Инвентисбио Инк. | Ингибиторы индоламин-2,3-диоксигеназы (ido) |
| AU2017226005A1 (en) * | 2016-03-01 | 2018-09-06 | Propellon Therapeutics Inc. | Inhibitors of WDR5 protein-protein binding |
| US11319299B2 (en) | 2016-03-01 | 2022-05-03 | Propellon Therapeutics Inc. | Substituted carboxamides as inhibitors of WDR5 protein-protein binding |
| CN107382840B (zh) | 2016-05-16 | 2020-09-01 | 四川大学 | 吡啶类化合物及其作为idh功能变异突变体抑制剂类药物的用途 |
| WO2019127385A1 (en) | 2017-12-29 | 2019-07-04 | Shenzhen United Imaging Healthcare Co., Ltd. | Systems and methods for patient positioning |
| CN108715585A (zh) | 2018-04-23 | 2018-10-30 | 中国药科大学 | 苯基联三氮唑类mll1-wdr5蛋白-蛋白相互作用抑制剂 |
-
2018
- 2018-04-23 CN CN201810365880.0A patent/CN108715585A/zh active Pending
- 2018-12-25 EA EA202092317A patent/EA202092317A1/ru unknown
- 2018-12-25 BR BR112020021569-4A patent/BR112020021569A2/pt unknown
- 2018-12-25 CN CN201880092659.0A patent/CN112368268A/zh active Pending
- 2018-12-25 CA CA3097925A patent/CA3097925A1/en active Pending
- 2018-12-25 KR KR1020207033699A patent/KR20210019414A/ko active IP Right Grant
- 2018-12-25 IL IL278255A patent/IL278255B2/en unknown
- 2018-12-25 WO PCT/CN2018/123500 patent/WO2019205687A1/zh active Application Filing
- 2018-12-25 MX MX2020011205A patent/MX2020011205A/es unknown
- 2018-12-25 EP EP18916025.2A patent/EP3786157B1/en active Active
- 2018-12-25 SG SG11202010492SA patent/SG11202010492SA/en unknown
- 2018-12-25 AU AU2018420231A patent/AU2018420231B2/en active Active
- 2018-12-25 JP JP2020558628A patent/JP7274765B2/ja active Active
-
2020
- 2020-10-22 US US17/078,052 patent/US11479545B2/en active Active
- 2020-10-22 PH PH12020551756A patent/PH12020551756A1/en unknown
- 2020-10-22 ZA ZA2020/06581A patent/ZA202006581B/en unknown
- 2020-10-22 CL CL2020002736A patent/CL2020002736A1/es unknown
- 2020-11-20 CO CONC2020/0014430A patent/CO2020014430A2/es unknown
-
2022
- 2022-09-14 US US17/944,757 patent/US12054478B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN112368268A (zh) | 2021-02-12 |
| IL278255B1 (en) | 2023-05-01 |
| EA202092317A1 (ru) | 2021-07-23 |
| CN108715585A (zh) | 2018-10-30 |
| US20230098016A1 (en) | 2023-03-30 |
| EP3786157B1 (en) | 2024-08-07 |
| AU2018420231A1 (en) | 2020-12-10 |
| AU2018420231B2 (en) | 2024-08-22 |
| JP7274765B2 (ja) | 2023-05-17 |
| US11479545B2 (en) | 2022-10-25 |
| SG11202010492SA (en) | 2020-11-27 |
| US20210139466A1 (en) | 2021-05-13 |
| CA3097925A1 (en) | 2019-10-31 |
| EP3786157A4 (en) | 2022-01-05 |
| BR112020021569A2 (pt) | 2021-04-13 |
| WO2019205687A1 (zh) | 2019-10-31 |
| PH12020551756A1 (en) | 2021-08-16 |
| JP2021525226A (ja) | 2021-09-24 |
| ZA202006581B (en) | 2023-05-31 |
| EP3786157A1 (en) | 2021-03-03 |
| IL278255B2 (en) | 2023-09-01 |
| CL2020002736A1 (es) | 2021-05-28 |
| US12054478B2 (en) | 2024-08-06 |
| CO2020014430A2 (es) | 2021-05-20 |
| IL278255A (es) | 2020-12-31 |
| KR20210019414A (ko) | 2021-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551756A1 (en) | Phenyl triazole mll1-wdr5 protein-protein interaction inhibitor | |
| MX2021014441A (es) | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. | |
| MX2021014443A (es) | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. | |
| ZA202108443B (en) | Protein tyrosine phosphatase inhibitors | |
| MX2021012589A (es) | Derivados de piperidina como inhibidores de proteasa especifica de ubiquitina 7. | |
| IL304534A (en) | kras g12c inhibitors | |
| CR20220351A (es) | Inhibidores de proteínas kras mutantes | |
| IL286373A (en) | Protein tyrosine phosphatase inhibitor compounds and uses thereof | |
| MX2020007799A (es) | Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos. | |
| CY1120988T1 (el) | Παρεμποδιστες διαρυλ κινασης | |
| EP3833350A4 (en) | PYRROLOPYRIMIDINE TKI INHIBITORS | |
| IL276813A (en) | Arginase inhibitors | |
| MX2020006612A (es) | Compuesto que funciona como inhibidor de proteína de bromodominio y composición. | |
| IL279952A (en) | Triazole glycolate oxidase inhibitors | |
| HUE065501T2 (hu) | A KEAP1-NRF2 protein-protein kölcsönhatás inhibitorok | |
| MX2017013875A (es) | Ciertos inhibidores de la proteína quinasa. | |
| EP4043458A4 (en) | EP300/CBP INHIBITORS | |
| CL2022001452A1 (es) | Inhibidores de masp-2 y métodos de uso. | |
| ZA202109737B (en) | Compound used as kinase inhibitor and application thereof | |
| ZA202202245B (en) | Quinoline derivatives as protein kinase inhibitors | |
| IL289773A (en) | Disubstituted amino triazoles are useful as chitinase inhibitors | |
| IL279419A (en) | CCL5 inhibitors | |
| EP3915636A4 (en) | HYDRAZIDE COMPOUND AND KINASE INHIBITOR | |
| EP4025564A4 (en) | NITRIFICATION INHIBITORS | |
| ZA202201899B (en) | Substituted amino triazoles useful as chitinase inhibitors |